Journal
AUSTRALASIAN JOURNAL OF DERMATOLOGY
Volume 62, Issue 3, Pages 390-393Publisher
WILEY
DOI: 10.1111/ajd.13642
Keywords
biologic; Ilumya; nail; psoriasis; tildrakizumab
Categories
Ask authors/readers for more resources
Tildrakizumab has shown significant improvement in treating treatment resistant nail psoriasis with no observed side effects. This medication presents a promising option in managing patients with this type of psoriasis.
Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL-23 inhibitor, has shown significant clinical improvement in the treatment of moderate-to-severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off-label tildrakizumab. The dosing regimen utilised was consistent with that used to treat chronic plaque psoriasis, with 100 mg subcutaneously at Day 0 and Week 4, and maintenance dosing of 100 mg every 12 weeks thereafter. Significant improvement at 6 and 12 months, as per the modified Nail Psoriasis Severity Index (mNAPSI) and Dermatology Life Quality Index (DLQI), was seen. There have been no tildrakizumab related side effects observed to date. Tildrakizumab appears to be an effective option in managing treatment resistant nail psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available